CN103025738B - 呋喃并吡啶化合物及其用途 - Google Patents

呋喃并吡啶化合物及其用途 Download PDF

Info

Publication number
CN103025738B
CN103025738B CN201180030410.5A CN201180030410A CN103025738B CN 103025738 B CN103025738 B CN 103025738B CN 201180030410 A CN201180030410 A CN 201180030410A CN 103025738 B CN103025738 B CN 103025738B
Authority
CN
China
Prior art keywords
methyl
amino
pyridine
furo
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180030410.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN103025738A (zh
Inventor
D·巴尔内斯
R·乔普拉
S·L·科恩
傅继平
加藤充典
P·卢
M·西迫索德
张巍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN103025738A publication Critical patent/CN103025738A/zh
Application granted granted Critical
Publication of CN103025738B publication Critical patent/CN103025738B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CN201180030410.5A 2010-04-21 2011-04-20 呋喃并吡啶化合物及其用途 Expired - Fee Related CN103025738B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32649110P 2010-04-21 2010-04-21
US61/326,491 2010-04-21
PCT/EP2011/056304 WO2011131709A1 (en) 2010-04-21 2011-04-20 Furopyridine compounds and uses thereof

Publications (2)

Publication Number Publication Date
CN103025738A CN103025738A (zh) 2013-04-03
CN103025738B true CN103025738B (zh) 2015-08-19

Family

ID=44010017

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180030410.5A Expired - Fee Related CN103025738B (zh) 2010-04-21 2011-04-20 呋喃并吡啶化合物及其用途

Country Status (9)

Country Link
US (1) US8324239B2 (https=)
EP (1) EP2560976B9 (https=)
JP (1) JP5756850B2 (https=)
CN (1) CN103025738B (https=)
AR (1) AR082453A1 (https=)
ES (1) ES2605039T3 (https=)
TW (1) TW201139446A (https=)
UY (1) UY33348A (https=)
WO (1) WO2011131709A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG189985A1 (en) 2010-10-26 2013-06-28 Presidio Pharmaceuticals Inc Inhibitors of hepatitis c virus
WO2013163466A1 (en) * 2012-04-25 2013-10-31 Presidio Pharmaceuticals, Inc. Inhibitors of hepatitis c virus
TWI731854B (zh) * 2015-03-23 2021-07-01 美商共結晶製藥公司 Ｃ型肝炎病毒聚合酶之抑制劑
AU2016258192B2 (en) 2015-05-06 2021-07-29 Leidos Biomedical Research, Inc. K-Ras modulators
EP3612526A2 (en) 2017-04-20 2020-02-26 The Regents of the University of California K-ras modulators
JP7237941B2 (ja) * 2017-05-19 2023-03-13 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置用の融合複素環式芳香族アニリン化合物
WO2019204449A1 (en) * 2018-04-18 2019-10-24 Theras, Inc. K-ras modulators with a vinyl sulfone moiety
CN108727309B (zh) * 2018-06-20 2023-04-07 天津全和诚科技有限责任公司 一种3-氧杂环丁烷羧酸的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007059422A2 (en) * 2005-11-10 2007-05-24 Wyeth Pharmaceutical formulations containing 5-cyclopropyl-2(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl) amino]-n-methyl-1-benzofuran-3-carboxamide and method of making same
WO2009137500A1 (en) * 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2010030538A2 (en) * 2008-09-11 2010-03-18 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383A (en) 1846-02-10 Improvement in condensing steam and feeding steam-boilers
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
KR0148748B1 (ko) 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
DE69133402T2 (de) 1990-04-04 2004-11-11 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Protease von hepatitis-c-virus
DE69434931T2 (de) 1993-04-02 2007-11-22 Rigel Pharmaceuticals, Inc., South San Francisco Methode zur selektiven inaktivierung der viralen replication
IT1272179B (it) 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
US5703116A (en) 1995-04-18 1997-12-30 Geron Corporation Telomerase Inhibitors
US5861267A (en) 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
WO1997012033A1 (en) 1995-09-27 1997-04-03 Emory University Recombinant hepatitis c virus rna replicase
US5759795A (en) 1996-03-08 1998-06-02 Schering Corporation Assay for determining inhibitors of ATPase
CA2283379A1 (en) 1997-03-05 1998-09-11 Michael G. Katze Novel screening methods to identify agents that selectively inhibit hepatitis c virus replication
CA2312484A1 (en) 1997-12-11 1999-06-17 Smithkline Beecham Corporation Hepatitis c virus ns5b truncated protein and methods thereof to identify antiviral compounds
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
WO2002051849A1 (en) 2000-12-26 2002-07-04 Daiichi Pharmaceutical Co., Ltd. Cdk4 inhibitors
WO2002072549A1 (en) 2001-03-12 2002-09-19 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
EP1558252B1 (en) 2002-08-02 2007-10-10 Merck & Co., Inc. Substituted furo [2,3-b]pyridine derivatives
AU2003264038A1 (en) 2002-08-12 2004-02-25 Bristol-Myers Squibb Company Combination pharmaceutical agents as inhibitors of hcv replication
AU2003279230A1 (en) 2002-10-09 2004-05-04 Scios Inc. AZAINDOLE DERIVATIVES AS INHIBITORS OF p38 KINASE
EA009943B1 (ru) 2002-11-01 2008-04-28 Вирофарма Инкорпорейтед Соединения бензофурана, композиции и способы лечения и профилактики инфекций, вызванных вирусом гепатита с, и связанных с ним заболеваний
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
JP2006524672A (ja) 2003-04-25 2006-11-02 ユニバーシティー・カッレッジ・カーディフ・コンサルタンツ・リミテッド ウイルス感染の治療において使用するための複素環式化合物
EP1648455A4 (en) 2003-07-23 2009-03-04 Exelixis Inc MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
JP2007501189A (ja) 2003-08-01 2007-01-25 ジェネラブス テクノロジーズ，インコーポレイテッド フラビウイルス科に対する二環式イミダゾール誘導体
UY28526A1 (es) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
TW200528459A (en) 2004-01-06 2005-09-01 Achillion Pharmaceuticals Inc Azabenzofuran substituted thioureas; inhibitors of viral replication
CA2553670A1 (en) 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc. Anti-viral therapeutics
WO2005080377A1 (ja) 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
JPWO2005082905A1 (ja) 2004-02-26 2007-08-02 協和醗酵工業株式会社 二環性複素環化合物
WO2005112932A2 (en) 2004-05-07 2005-12-01 Exelixis, Inc. Raf modulators and methods of use
US7569604B2 (en) 2004-06-22 2009-08-04 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives for modulation of calcium channels
TW200618800A (en) 2004-08-03 2006-06-16 Uriach Y Compania S A J Heterocyclic compounds
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
MX2007004783A (es) 2004-10-21 2007-05-11 Pfizer Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan.
WO2007084667A2 (en) 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Fused heterobicyclic kinase inhibitors
AU2007275221A1 (en) 2006-07-20 2008-01-24 Allen J. Borchardt Benzothiophene inhibitors of RHO kinase
WO2008057856A2 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof
WO2008057857A1 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
MX2009008439A (es) 2007-02-12 2009-08-13 Intermune Inc Nuevos inhibidores de la replicacion del virus de hepatitis c.
WO2008108309A1 (ja) 2007-03-02 2008-09-12 Kyowa Hakko Kirin Co., Ltd. 縮環ピリジン誘導体
PE20090142A1 (es) 2007-04-11 2009-02-19 Merck & Co Inc Derivados de furo[2,3-b] piridina sustituidos como moduladores del receptor canabinoide-1
GB0707000D0 (en) 2007-04-12 2007-05-30 Istituto Di Ricerche D Biolog Antiviral agents
RS52518B (sr) 2007-04-23 2013-04-30 Janssen Pharmaceutica N.V. Derivati 4-alkoksipiridazina kao brzo disocirajući dopamin 2 receptorski antagonisti
EA019749B1 (ru) 2007-06-29 2014-06-30 Джилид Сайэнс, Инк. Противовирусные соединения
WO2009027732A1 (en) 2007-08-24 2009-03-05 Astrazeneca Ab 5-6-bicyclic heteroaromatic compounds with antibacterial activity
WO2009041591A1 (ja) 2007-09-28 2009-04-02 Kyowa Hakko Kirin Co., Ltd. 縮環ピリジン誘導体
ATE539070T1 (de) 2008-02-14 2012-01-15 Hoffmann La Roche Heterozyklische antivirale verbindungen
US8546410B2 (en) 2008-05-05 2013-10-01 Abbvie Inc. Heteroaryl-fused macrocyclic pyrimidine derivatives
US8048887B2 (en) 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007059422A2 (en) * 2005-11-10 2007-05-24 Wyeth Pharmaceutical formulations containing 5-cyclopropyl-2(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl) amino]-n-methyl-1-benzofuran-3-carboxamide and method of making same
WO2009137500A1 (en) * 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2010030538A2 (en) * 2008-09-11 2010-03-18 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c

Also Published As

Publication number Publication date
CN103025738A (zh) 2013-04-03
UY33348A (es) 2011-12-01
EP2560976A1 (en) 2013-02-27
US20120015907A1 (en) 2012-01-19
JP2013527842A (ja) 2013-07-04
TW201139446A (en) 2011-11-16
US8324239B2 (en) 2012-12-04
AR082453A1 (es) 2012-12-12
ES2605039T3 (es) 2017-03-10
EP2560976B9 (en) 2017-06-07
JP5756850B2 (ja) 2015-07-29
WO2011131709A1 (en) 2011-10-27
EP2560976B1 (en) 2016-08-24

Similar Documents

Publication Publication Date Title
CN103025738B (zh) 呋喃并吡啶化合物及其用途
ES2634095T3 (es) Compuestos antivíricos
TWI465444B (zh) 抗病毒化合物
JP2018024705A (ja) 抗ウイルス化合物としての縮合イミダゾリルイミダゾール
CN111801331A (zh) 吲哚-2-羰基化合物及其用于治疗乙型肝炎的用途
TW201014855A (en) Compounds for the treatment of hepatitis C
CN111433210A (zh) 作为抗病毒药的稠合三环吡唑并-二氢吡嗪基-吡啶酮化合物
CN106029076A (zh) 作为bet溴域抑制剂的苯并哌嗪组合物
CN106470990A (zh) 哒嗪化合物
EP2597095A1 (en) Fused heterocyclic compound and application thereof
CN103025728B (zh) 2,3,5-三取代的噻吩化合物及其用途
TWI862653B (zh) 雜環化合物
HK40072079B (zh) 杂环化合物
HK1236946B (zh) 抗病毒化合物
TW201247656A (en) 2,3,5-trisubstituted thiophene compounds and uses thereof
TW201444828A (zh) 可作爲溴區結構域蛋白抑制劑之咔唑化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Basel, Switzerland

Applicant after: NOVARTIS AG

Address before: Basel, Switzerland

Applicant before: Novartis AG

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: NOVARTIS AG TO: NOVARTIS CO., LTD.

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150819

CF01 Termination of patent right due to non-payment of annual fee